Timothy Kristedja, M.D.
Dr. Timothy Kristedja is one of the oncologists who are currently affiliated with Cedars-Sinai Marina del Rey Hospital. He is a prolific author, having conducted extensive research activity and published multiple studies. The physician has a Bachelor of Science in Biochemistry, which he earned from California Polytechnic State University, and a Master of Public Health in Health Services-Management Track, which he received from UCLA School of Public Health. Subsequently, Dr. Timothy Kristedja earned his medical degree from Trinity College Dublin, School of Medicine. His professional training also includes a residency in Internal Medicine at the University of Arizona and a Fellowship in Hematology and Medical Oncology at Harbor UCLA Medical Center/City of Hope Comprehensive Cancer Center.
Dr. Timothy Kristedja primarily focuses his medical practice on providing compassionate, expert, and personalized care in the treatment of benign blood disorders, hematologic malignancies, and solid tumors. He is board-certified in internal medicine, medical oncology, and hematology, and he also serves as a Clinical Instructor in Oncology at Harbor-UCLA Medical Center. His clinical research has led to many peer-reviewed publications in multiple subject areas, including malignant melanoma and pancreatic and ovarian cancer. The physician has over 15 years of professional experience.
Conditions Dr. Timothy Kristedja Treats at Cedars-Sinai Marina del Rey Hospital
Insurance Accepted
- Aetna
- Medicare
- United Healthcare
- Blue Cross / Blue Shield
- Blue Shield of California
- CareFirst BCBS
- Cigna
- MultiPlan
- Coventry Health Care
Languages Spoken
- English
- Russian
- Spanish
Education & Training
Medical Degree
Trinity College Dublin, School of Medicine Dublin
Internship(s)
University of Arizona Health Sciences Center
Residency(ies)
University of Arizona - Internal Medicine
Fellowship(s)
Harbor UCLA Medical Center/City of Hope Comprehensive Cancer Center - Hematology and Medical Oncology
Publications & Media
-
Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma.
O'Day SJ, Gammon G, Boasberg PD, Martin MA, Kristedja TS, Guo M, Stern S, Edwards S, Fournier P, Weisberg M, Cannon M, Fawzy NW, Johnson TD, Essner R, Foshag LJ, Morton DL
-
Biochemotherapy for metastatic melanoma with limited central nervous system involvement.
Boasberg, P. D., O'Day, S. J., Kristedja, T. S., Martin, M., Wang, H., Deck, R., Shinn, K., Ames, P., Tamar, B., Petrovich, Z.
-
Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
Liu, D., O'Day, S. J., Yang, D., Boasberg, P., Milford, R., Kristedja, T., Groshen, S., Weber, J.
-
Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma.
Boasberg, P.D., Hoon, D.B., Piro, L.D., Martin, M.A., Fujimoto, A., Kristedja, T.S., Bhachu, S., Ye, X., Deck, R.R., O'Day, S.J.
-
Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
O'Day, S.J., Boasberg, P.D., Piro, L., Kristedja, T.S., Wang, H., Martin, M., Deck, R., Ames, P., Shinn, K., Kim, H., Fournier, P., Gammon, G.
-
High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma.
O'Day, S. J., Boasberg, P. D., Kristedja, T. S., Martin, M., Wang, H. J., Fournier, P., Cabot, M., DeGregorio, M. W., Gammon, G.